EP3843759
Notkun á æxlis-ífarandi eitilfrumum til meðhöndlunar á NSCLC sjúklingum sem eru andstæðir and-PD-1 mótefni
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
3.9.2019EP published:
14.2.2024EP application number:
19856433.8
EP translation filed:
10.5.2024Grant published:
15.6.2024EPO information:
European Patent Register
Max expiry date:
2.9.2039Expiry date:
2.9.2026Next due date:
30.9.2026
Title in English:
USE OF TUMOR INFLITRATING LYMPHOCYTES FOR TREATING NSCLC PATIENTS REFRACTORY FOR ANTI-PD-1 ANTIBODYLanguage of the patent:
English
Timeline
Today
3.9.2019EP application
14.2.2024EP Publication
10.5.2024Translation submitted
15.6.2024Registration published
2.9.2026Expires
Owner
Name:
Iovance Biotherapeutics, Inc.Address:
825 Industrial Road Suite 400, San Carlos, CA 94070, US
Inventor
Name:
FARDIS, MariaAddress:
San Carlos, CA 94070, US
Name:
NATARAJAN, ArvindAddress:
Basking Ridge, NJ 07920, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201862725976 PDate:
31.8.2018Country:
US
Number:
201862726919 PDate:
4.9.2018Country:
US
Classification
Categories:
A61K 35/17, A61K 45/06, C12N 5/0781, C12N 5/0783, A61P 35/00
Annual fees
Number
Paid
Expires
Payer
Number: 6
Paid: 22.8.2024
Expires: 2.9.2025
Payer: Árnason Faktor ehf.
Number: 7
Paid: 21.8.2025
Expires: 2.9.2026
Payer: Árnason Faktor ehf.